This is Novavax's Biggest Challenge Right Now

Novavax (NASDAQ: NVAX) is readying itself for the potential launch of its coronavirus vaccine candidate. The company has built out a significant manufacturing network. But the path hasn't been completely smooth. In this Motley Fool Live video recorded on June 22, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss a possible roadblock -- one that's already slowed Novavax's path to commercialization.

Continue reading

Source Fool.com